These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35216261)

  • 41. Physicochemical characterization of ferric pyrophosphate citrate.
    Gupta A; Pratt R; Mishra B
    Biometals; 2018 Dec; 31(6):1091-1099. PubMed ID: 30324285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
    Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
    Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents.
    Preusser LC; Fryer RM; Gerhardt A; Hu Y; Delgado-Herrera L; Melnick JZ; Williams LA; Cox BF; Reinhart GA
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1020-6. PubMed ID: 16445566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypersensitivity from intravenous iron products.
    Bircher AJ; Auerbach M
    Immunol Allergy Clin North Am; 2014 Aug; 34(3):707-23, x-xi. PubMed ID: 25017687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model.
    Klapproth AP; Shevtsov M; Stangl S; Li WB; Multhoff G
    Int J Nanomedicine; 2020; 15():4677-4689. PubMed ID: 32669844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aspects of the stability and bioavailability of carbohydrates and carbohydrate derivatives.
    Drinnan NB; Vari F
    Mini Rev Med Chem; 2003 Nov; 3(7):633-49. PubMed ID: 14529505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Irritative effects of intravenous administration of iron-glucose solutions].
    WIESENER H
    Dtsch Med J; 1952 Jun; 3(11-12):253-4. PubMed ID: 12979956
    [No Abstract]   [Full Text] [Related]  

  • 48. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
    Neiser S; Koskenkorva TS; Schwarz K; Wilhelm M; Burckhardt S
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.
    Floege J; Funk F; Ketteler M; Rastogi A; Walpen S; Covic AC; Sprague SM
    Nephrol Dial Transplant; 2020 Jun; 35(6):946-954. PubMed ID: 32259248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antibody formation in children after massive single intravenous doses of iron oxide saccarates].
    HAGBERG B
    Nord Med; 1953 Feb; 49(7):252-5. PubMed ID: 13055011
    [No Abstract]   [Full Text] [Related]  

  • 51. [Distribution of ferritin in the organs of normal and splenectomized dogs after intravenous administration of iron].
    TECCE G; TEDESCHI G
    Boll Soc Ital Biol Sper; 1952 Jul; 28(7):1391-3. PubMed ID: 13018784
    [No Abstract]   [Full Text] [Related]  

  • 52. A new iron-carbohydrate complex: hematopoietic effect and a double-blind tolerance study.
    HOFFMAN EP; WILSON WL
    Curr Ther Res Clin Exp; 1961 Sep; 3():387-92. PubMed ID: 13715013
    [No Abstract]   [Full Text] [Related]  

  • 53. Quantitative assessment of the metabolic products of iron oxide nanoparticles to be used as iron supplements in cell cultures.
    Fernández JG; Sánchez-González C; Bettmer J; Llopis J; Jakubowski N; Panne U; Montes-Bayón M
    Anal Chim Acta; 2018 Dec; 1039():24-30. PubMed ID: 30322549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iron from complex salts and its bioavailability to rats.
    Dutra-de-Oliveira JE; Freitas ML; Ferreira JF; Gonçalves AL; Marchini JS
    Int J Vitam Nutr Res; 1995; 65(4):272-5. PubMed ID: 8789625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron oxide/gold core/shell nanoparticles for ultrasensitive detection of carbohydrate-protein interactions.
    Liang CH; Wang CC; Lin YC; Chen CH; Wong CH; Wu CY
    Anal Chem; 2009 Sep; 81(18):7750-6. PubMed ID: 19689135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Blood protein modifications after oral and intravenous iron load].
    VALENTE R
    Rass Fisiopatol Clin Ter; 1951; 23(2-12):355-69. PubMed ID: 14930263
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?
    Gupta A; Crumbliss AL
    J Lab Clin Med; 2000 Nov; 136(5):371-8. PubMed ID: 11079464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: impact on macrophage uptake.
    Lartigue L; Wilhelm C; Servais J; Factor C; Dencausse A; Bacri JC; Luciani N; Gazeau F
    ACS Nano; 2012 Mar; 6(3):2665-78. PubMed ID: 22324868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
    Funk F; Ryle P; Canclini C; Neiser S; Geisser P
    Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biodistribution and Toxicity Assessment of Superparamagnetic Iron Oxide Nanoparticles In Vitro and In Vivo.
    Yu Q; Xiong XQ; Zhao L; Xu TT; Bi H; Fu R; Wang QH
    Curr Med Sci; 2018 Dec; 38(6):1096-1102. PubMed ID: 30536075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.